Core Viewpoint - Huatai Securities reported that CSPC Pharmaceutical Group's revenue for the first three quarters was 19.89 billion yuan, a year-on-year decrease of 12.3%, while net profit was 3.51 billion yuan, down 7.1% year-on-year [1] Group 1: Financial Performance - The company's revenue returned to growth in the third quarter, primarily due to a narrowing decline in the prescription drug business after excluding authorized income, and the gradual dissipation of the impact from the procurement of Dumex [1] - The profit for the third quarter was 960 million yuan, with the firm estimating nearly 600 million yuan in organic profit [1] Group 2: Future Outlook - Looking ahead to the fourth quarter, the firm is optimistic about the continuous market expansion of new products such as Omaguzumab and Mingfule, expecting ongoing improvement in revenue on a quarterly basis [1] - The firm maintains a "buy" rating on the company, considering the potential of the EGFR ADC's significant overseas market opportunities, other business development opportunities from the company's technology platforms, and potential data readouts from significant pipelines [1] Group 3: Profit Forecast and Target Price - The firm has revised its net profit forecasts for the company for 2025 to 2027 from 5.753 billion, 5.783 billion, and 6.771 billion yuan down to 4.552 billion, 4.628 billion, and 5.029 billion yuan respectively [1] - The target price has been reduced from 16.48 HKD to 12.75 HKD [1]